Apellis Pharmaceuticals Inc’s recently made public that its General Counsel Watson David O. unloaded Company’s shares for reported $0.14 million on Jan 13 ’25. In the deal valued at $28.70 per share,4,965 shares were sold. As a result of this transaction, Watson David O. now holds 107,756 shares worth roughly $2.98 million.
Then, Townsend Adam J. sold 2,685 shares, generating $77,065 in total proceeds. Upon selling the shares at $28.70, the Chief Commercial Officer now owns 90,269 shares.
Before that, Sullivan Timothy Eugene sold 2,170 shares. Apellis Pharmaceuticals Inc shares valued at $62,284 were divested by the Chief Financial Officer at a price of $28.70 per share. As a result of the transaction, Sullivan Timothy Eugene now holds 88,100 shares, worth roughly $2.44 million.
Goldman downgraded its Apellis Pharmaceuticals Inc [APLS] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in late November with a ‘”an Equal-weight”‘ rating. RBC Capital Mkts began covering APLS with “Sector perform” recommendation on October 25, 2024. William Blair started covering the stock on October 16, 2024. It rated APLS as “an Outperform”.
Price Performance Review of APLS
On Tuesday, Apellis Pharmaceuticals Inc [NASDAQ:APLS] saw its stock fall -3.15% to $27.69. Over the last five days, the stock has lost -19.46%. Apellis Pharmaceuticals Inc shares have fallen nearly -13.22% since the year began. Nevertheless, the stocks have fallen -58.10% over the past one year. While a 52-week high of $71.90 was reached on 01/07/25, a 52-week low of $24.34 was recorded on 01/10/25. SMA at 50 days reached $31.44, while 200 days put it at $37.29.
Levels Of Support And Resistance For APLS Stock
The 24-hour chart illustrates a support level at 27.12, which if violated will result in even more drops to 26.54. On the upside, there is a resistance level at 28.76. A further resistance level may holdings at 29.82. The Relative Strength Index (RSI) on the 14-day chart is 34.11, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.12, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.86%. Stochastics %K at 6.77% indicates the stock is a buying.
How much short interest is there in Apellis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Apellis Pharmaceuticals Inc stocks on 2024-12-31, dropping by -0.33 million shares to a total of 21.48 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 21.81 million shares. There was a decline of -1.55%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 16, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating .
